Spearmint Extract Improves Working Memory in Men and Women with Age-Associated Memory Impairment by Herrlinger, KA et al.
Spearmint Extract Improves Working Memory in Men
and Women with Age-Associated Memory Impairment
Kelli A. Herrlinger, MS,1 Kristin M. Nieman, PhD,2,* Kristen D. Sanoshy, MPH,2
Brenda A. Fonseca, MA,1 Joanne A. Lasrado, PhD,1 Arianne L. Schild, MS,2
Kevin C. Maki, PhD,2,** Keith A. Wesnes, PhD,3–5,{ and Michael A. Ceddia, PhD1
Abstract
Objective: The purpose of this study was to investigate the effects of supplementation with a spearmint
(Mentha spicata L.) extract, high in polyphenols including rosmarinic acid, on cognitive performance, sleep,
and mood in individuals with age-associated memory impairment (AAMI).
Design: Subjects with AAMI (N = 90; 67% female; age = 59.4– 0.6 years) were randomly assigned (n= 30/
group) to consume 900, 600, or 0mg/day (two capsules, once daily) spearmint extract for 90 days, in this
double-blind, placebo-controlled trial. Assessments were completed for cognition (days 0, 45, and 90), sleep
(days 0 and 90), and mood (days 0 and 90) by using the Cognitive Drug Research (CDR) System, Leeds Sleep
Evaluation Questionnaire (LSEQ), and Profile of Mood States (POMS), respectively.
Results: Quality of working memory and spatial working memory accuracy improved after supplementation
with 900mg/day spearmint extract by 15% ( p = 0.0469) and 9% ( p= 0.0456), respectively, versus placebo.
Subjects consuming 900mg/day spearmint extract reported improvement in their ability to fall asleep, relative to
subjects consuming placebo ( p= 0.0046). Overall treatment effects were evident for vigor-activity ( p= 0.0399),
total mood disturbance ( p= 0.0374), and alertness and behavior following wakefulness ( p= 0.0415), with trends
observed for improvements after spearmint supplementation relative to placebo.
Conclusions: These results suggest that the distinct spearmint extract may be a beneficial nutritional inter-
vention for cognitive health in older subjects with AAMI.
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Introduction
Aging is commonly associated with deficits in cognitivedomains, including speed of processing, working mem-
ory capacity, and long-term memory. Age-associated memory
impairment (AAMI) is a nonpathological condition that is
frequently observed as a result of normal brain aging.1 With
the number of older adults (>65 years of age) worldwide
expected to more than double by the year 2030 and average
life span predicted to extend by 10 years by 2050, cognitive
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decline threatens quality of life and creates challenges for
healthcare systems.2 Thus, the need for effective interven-
tions that are aimed at maintaining cognitive health or
slowing cognitive decline is critical.
Various nutrients and botanical ingredients have been
investigated for their neurocognitive benefits, with studies
reporting varying degrees of efficacy.3–9 A few studies have
reported positive acute effects on cognition after the con-
sumption of plant extracts from the Lamiaceae family,10–12
which some research suggests may be attributed to the
polyphenols contained in these plants and their extracts.
Specifically, polyphenols found in plants within the La-
miaceae family, such as rosmarinic and salvianolic acids,
have been shown to have anticholinesterase and antioxidant
activity, as well as additional neuroprotective and neuro-
trophic effects both in vitro and in vivo,13–15 all which
provide biological plausibility for the potential cognitive
benefits of extracts derived from this plant group.
Systemic accumulation of free radical and oxidation end
products have been inversely correlated with cognitive
function.16 Extracts from plants within Lamiaceae family
have been shown to have antioxidant capacity and the
ability to reduce systemic and local inflammation.17,18
Specifically, rosmarinic acid (RA) has been shown to pro-
mote antioxidant status in both neuronal cells and hippo-
campal tissue.13,15 In addition, salvianolic acid, an RA
dimer and compound detected in the spearmint extract tes-
ted, has been shown to promote anti-inflammatory and
antioxidative effects in a mouse model of Alzheimer’s dis-
ease.19 Therefore, it is plausible that other phenolic com-
pounds within the spearmint extract, in addition to RA, may
contribute to the observed benefits.
Spearmint (Mentha spicataL.) lines were developed through
traditional breeding techniques to produce significantly higher
levels of bioactive polyphenols, such as RA,20 to study the
effects of these polyphenols on cognitive function. These
spearmint lines are distinct from typical commercially available
spearmint because they do not contain certain constituents, such
as carvone, and they contain 8–9% RA compared with 0–6%
RA on a dry weight basis reported for other plants within the
Lamiaceae species.20,21 The first indications that the dried
aqueous extract from this spearmint could support cognitive
performance were obtained by using a senescence accelerated
mouse-prone 8 (SAMP8) model of aging.22 When the spear-
mint extract was administered to SAMP8 mice for 12 weeks at
320mg/kg bodyweight, improvements in learning andmemory
occurred that corresponded to reduced protein carbonyls and
3-nitrotyrosine in the hippocampus. This reduction in oxidation
byproducts in the hippocampus is a plausible mechanism of
action for the cognitive effects of spearmint extract supple-
mentation. Further, since working memory is reported to be
hippocampally dependent,23 it is plausible that spearmint ex-
tract could favorably impact working memory. These initial
findings were subsequently corroborated by an open-label
clinical study in which healthy older subjects with self-reported
memory impairment consumed the extract for 30 days. This
study confirmed that the extract was well tolerated and im-
proved cognitive performance.24
Based on these positive findings, we hypothesized that
chronic daily consumption of the spearmint extract would
favorably impact cognition. Therefore, this study investi-
gated the effects of this dried aqueous spearmint extract on
cognitive performance, sleep, and mood in healthy older
subjects with AAMI.
Materials and Methods
Study design
This randomized, double-blind, placebo-controlled study
was conducted in accordance with Good Clinical Practice
FIG. 1. Study design overview. This double-blind, placebo-controlled, parallel study included one telephone screen, two
screening visits (days -14 and -7), a baseline visit (day 0), and two treatment visits (days 45 and 90). Subjects were
randomly assigned one of three treatments: 600mg spearmint extract, 900mg spearmint extract, or placebo, which was
consumed each day with breakfast over a 90-day treatment period. During baseline and treatment visits, subjects completed
the CDR System computerized cognitive function test battery (days 0, 45, and 90, at -0.75, 0.5, 2, 4, and 6 h), com-
puterized Profile of Mood States (days 0 and 90 only; at -0.75 h), and computerized Leeds Sleep Evaluation Questionnaire
(days 0 and 90 only; at -0.75 h). After their predose assessments, subjects consumed a standardized breakfast and one dose
of their assigned study product (0 h) followed by postdose computerized CDR test battery. CDR, Cognitive Drug Research.
Figure modified from Lasrado et al.27 and reproduced with permission.
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Guidelines, the Declaration of Helsinki,25 and the United
States 21 Code of Federal Regulations.26 An Institutional
Review Board (Quorum Review IRB, Seattle, Australia)
approved the study protocol as shown in Figure 1.
Subjects
Generally healthy men and women were recruited by the
Biofortis Clinical Research team by using an established
database of volunteers and local advertisements. Study visits
were conducted in the clinical research center in Addison,
IL, and eligible participants were identified based on the
inclusion and exclusion criteria outlined in Table 1.
Study product and treatment
The water-extracted dry proprietary spearmint (M. spicata
L. [aerial parts]) extract contained a minimum of 14.5% RA
and 24% total polyphenols (Kemin Foods, L.C., Des
Moines, IA).20,27–29 In addition, a compositional analysis of
this spearmint extract revealed the presence of other poly-
phenols and their derivatives, including, but not limited to,
RA, lithospermic, caftaric, and salvianolic A and B acids.29
Study capsules contained microcrystalline cellulose (place-
bo), or 300 or 450mg of the spearmint extract (Five-Star
Pharmacy, Clive, IA). Subjects were instructed to con-
sume two capsules with breakfast equivalent to 0, 600, or
900mg/day of extract for 90 days. Dose levels were identified
based on previous preclinical and clinical studies.22,24,28
Compliance was calculated as a percentage of study prod-
uct consumed according to the returned quantity of study
product and confirmed by a diary that subjects completed
daily.
Cognitive assessments
Cognitive performance was assessed by using the Cog-
nitive Drug Research (CDR) System (Bracket, LLC,
Wayne, PA). This computerized testing battery is validated
for populations with AAMI and has been shown to be sen-
sitive to acute and chronic nutritional interventions.4,10,30
The entire assessment was completed on laptop computers,
with the exception of the word recall test, which was
completed on paper. The cognitive performance assessment
was administered at -0.75, 0.5, 2, 4, and 6 h, where t = 0 h
was the time of product consumption at each visit (days 0,
45, and 90) based on previously published studies evaluating
botanical extracts in both humans and preclinical mouse
models of accelerated aging.4,12,22 Practice sessions, al-
lowing each subject to plateau, were completed at screening
to overcome any initial practice effects.31 In addition, par-
allel forms of the test were administered at each session to
reduce training effects.32
The assessment system consisted of 11 individual tasks to
assess attention and information processing, episodic and
working memory, executive function, and motor control.
The tasks were performed in the following order: immediate
word recall, simple reaction time, digit vigilance, choice
Table 1. Subject Inclusion/Exclusion Criteria
Inclusion criteria Exclusion criteria
50–70 Years of age Uncontrolled hypertension
Body–mass index between 18.5 and 35.0 kg/m2 Abnormal laboratory test results of clinical significance
Possessing at least a high school diploma History or presence of cancer, except nonmelanoma skin
cancerSubjects with AAMI were eligible based on the following
National Institute of Mental Health criteria,1,45 specified
as scoring:
‡25 on the MAC-Q46
£29 or £9 on the VPA I and II portions of the Wechsler
Memory Scale IV, respectively47
‡24 on the MMSE48
History or presence of clinically important cardiac, renal,
hepatic, endocrine, pulmonary, biliary, gastrointestinal,
pancreatic, or neurologic disorders (including sleep
disorders, head injuries, Alzheimer’s disease, Parkinson’s
disease, stroke, inflammatory brain disease)
Willing to maintain their habitual diet and exercise routines
History within previous 12 months of alcohol or substance
abuse
Willing to maintain consistent sleep duration the evening
before study visits
History of depression within past 24 months or use of
psychotropic medications within 1 month of screening
History of heavy smoking (>1 pack/day) within past 3
months
History of heavy caffeinated beverage consumption
(>400mg caffeine/day) within past 2 weeks
Women who were pregnant, lactating, or planning to be
pregnant during the study period or of childbearing
potential and unwilling to use a medically approved form
of contraception
Occupations that resulted in disruption of sleep-wake cycles
Use of medications or supplements known to alter cognitive
function within past 2 weeks
Inability to complete or understand the cognitive function
practice tests
AAMI, age-associated memory impairment; MAC-Q, Memory Assessment Clinic Scale Questionnaire; MMSE, Mini Mental State
Examination; VPA, Verbal Paired Associates.
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reaction time, numeric working memory, spatial working
memory, delayed word recall, word recognition, picture
recognition, tracking, and executive function. These tasks
have been previously described in detail,4 with the excep-
tion of the executive function task. The executive function
task requires judgments about the value or number of digits
in identical digit strings. Each battery took 30–45min and
was completed in an environment where temperature,
lighting, and noise were controlled. Composite factors were
calculated by combining individual task outcome scores as
previously described and depicted in Figure 2.4
Mood assessments
The Profile of Mood States (POMS Standard Form)
questionnaire was also incorporated into the computerized
assessment system and administered at days 0 and 90 during
the -0.75 h assessment to evaluate chronic differences in
mood.33 Ratings were combined into six factor composites:
tension-anxiety, depression-dejection, anger-hostility, vigor-
activity, fatigue-inertia, confusion-bewilderment, and a total
mood disturbance (TMD) score.33
Sleep assessment
The Leeds Sleep Evaluation Questionnaire (LSEQ) was
incorporated into the computerized assessment system and
administered at days 0 and 90 at the -0.75 h timepoint. This
validated questionnaire is a subjective evaluation of sleep
and results in four domains: ease of getting to sleep, quality
of sleep, awakening from sleep, and behavior following
wakefulness.34
Study procedures
Eligible subjects arrived at the clinic in the morning for
each test day (days 0, 45, and 90) after fasting (10–14 h) and
FIG. 2. Cognitive performance assessments diagram. The computerized cognitive performance test battery (CDR System;
Bracket, LLC, Wayne, PA) is summarized, indicating the tasks, outcome measures from each task, and the outcome
measures that contribute to the composite factors. CDR, Cognitive Drug Research. Figure modified from Pengelly et al.12
and reproduced with permission.
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body weight, compliance, and vital signs were assessed.
Subjects then completed the CDR test battery, POMS
questionnaire (days 0 and 90 only), and LSEQ (days 0 and
90 only) at the timepoints previously described. After that,
subjects consumed a standard breakfast meal (670 kcal: 59%
carbohydrates, 20% protein, 21% fat) with the assigned
treatment. Subjects were asked to avoid vigorous physical
activity (24 h), alcoholic beverages (24 h), caffeine (10–
14 h), and tobacco use (1 h) before and for the duration of all
test visits.
Statistical analysis
Sample size calculations were performed to test the dif-
ference between each active treatment and placebo. An
evaluable sample size of 27 subjects per group was expected
to provide 80% power (two-sided, a = 0.05) based on ability
to detect a 10% difference in quality of memory or power of
attention, independent domains of cognitive function uti-
lizing standard deviations from the CDR in healthy indi-
viduals older than 65 years of age after Salvia Officinalis
supplementation.10 A sample of 30 subjects per group
(N = 90) was randomized to account for attrition and non-
compliance (Fig. 3). Randomized subjects were stratified
based on smoking status.
Statistical analyses were conducted by using SAS version
9.2 (SAS Institute, Cary, NC) on the intent-to-treat (ITT)
population, which included all subjects who were random-
ized into the study, consumed at least one dose of study
product, and had at least one post-randomization outcome
data point. Baseline comparability of demographic variables
and all other outcomes were assessed by the analysis of
variance model. Changes from baseline (day 0) for cognitive
performance were evaluated by using daily averages of
scores at -0.75, 0.5, 2, 4, and 6 h of each visit. For outcome
measures administered once on a given test day (POMS and
LSEQ), change from baseline (day 0) was used for com-
parisons. Change scores were evaluated by a mixed-model
repeated-measures analysis containing the between-group
effect of treatment, the repeated-measures effect of time,
and the treatment · time interaction. All tests of significance
were completed at a = 0.05, two-tailed without adjustment
for multiple comparisons; thus, the possibility of Type I
error exists.
Results
Subjects
Subjects were recruited between August 2013 and Janu-
ary 2014 (Fig. 3), with baseline characteristics presented in
Table 2. Compliance was 98.1%– 0.9%, 99.1%– 0.8%, and
100.1%– 0.4% for the placebo, 600mg/day spearmint extract,
and 900mg/day spearmint extract groups, respectively. There
were no statistically significant differences in compliance
between treatment groups over the 90-day period. A total of
FIG. 3. Study flow diagram. A total of 198 subjects were screened. Men and women with age-associated memory
impairment were randomly assigned to one of three treatments: 0 (placebo), 600, or 900mg/day spearmint extract (N = 90;
n = 30/group). A total of 29, 28, and 30 subjects completed the trial in the placebo, 600mg/day spearmint extract, and
900mg/day spearmint extract groups, respectively. Three subjects withdrew from the study due to adverse events, including
knee pain, myalgia, headache, worsening of oily scalp, cystic acne, and heartburn. All adverse events were deemed ‘‘not
related’’ with the exception of heartburn, reported by one subject in the 600mg/day spearmint extract group, which was
deemed ‘‘probably related’’ to study product consumption. All available data were included in the intent-to treat population
(n = 28–30/group). AE, adverse event(s). Figure modified from Lasrado et al.27 and reproduced with permission.
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198 subjects were screened; 90 subjects were randomized to
treatment, consumed at least 1 dose of study product, and had
at least 1 post-randomization outcome data point that con-
stituted the ITT population (Fig. 3). Three participants did not
complete the study due to reported adverse events. Complete
results from the safety assessments are published elsewhere.27
Cognitive assessments
Composite factor scores on each test day are included in
Table 3. The CDR battery identified an overall treat-
ment effect in quality of working memory [F(2,84) = 3.25,
p = 0.0435] for subjects supplemented for 90 days with
spearmint extract (Fig. 4). Pairwise comparisons of the
change from baseline indicated that subjects who consumed
900mg/day extract had improved scores compared with
subjects who consumed either 600mg/day [t(84) =-2.35,
p = 0.0212, d = 0.546] extract or placebo [t(84)= 2.02,
p = 0.0469, d = 0.473]. The improvement in the 900mg/day
spearmint extract group over the 90-day supplementation
period was 22% compared with 5% and 7% in the 600mg/day
and placebo groups, respectively. Similarly, there was an
overall treatment effect after 90 days of spearmint extract
supplementation [F(2,84) = 3.42, p = 0.0373] in spatial
working memory (distractor items correctly identified, Fig. 5).
This improvement from baseline was significantly greater
for subjects consuming 900mg/day (17%) extract than subjects
consuming either 600mg/day [3%, t(84) = -2.43, p = 0.0172,
d = 0.563] extract or placebo [6%, t(84) = 2.03, p = 0.0456,
d=0.483] over the 90-day supplementation period. No addi-
tional statistically significant cognitive effects were detected.
Mood
Administration of the computerized POMS questionnaire
identified significant treatment effects in the vigor-activity
factor [F(2,82) = 3.35, p = 0.0399, Table 4] and the com-
posite TMD [F(2,82) = 3.42, p = 0.0374] after 90 days of
supplementation. However, significant differences in pair-
wise comparisons between either of the spearmint dose le-
vels and placebo were not evident. A trend for improvement
after 900mg spearmint, relative to placebo, was observed in
the vigor-activity factor [t(82)= 1.87, p = 0.646, d = 0.502].
Further, a significant effect in vigor-activity was also evi-
dent for subjects administered the 900 versus 600mg/day
dose level of spearmint extract [t(82) = -2.49, p = 0.0149,
d = 0.729]. No additional significant findings were observed
in the other individual mood parameters from the POMS.
Table 2. Baseline Characteristics of Subjects in the Intent-to-Treat Population
Parameter Overall Placebo
600mg
Spearmint
extract
900mg
Spearmint
extract p*
Gender, n (%) 0.4581
Male 30 (33) 9 (30) 8 (27) 13 (43)
Female 60 (67) 21 (70) 22 (73) 17 (57)
Ethnicity, n (%) 0.6125
Hispanic/Latino 5 (6) 1 (3) 1 (3) 3 (10)
Non-Hispanic/Latino 85 (94) 29 (97) 29 (97) 27 (90)
Race, n (%) 0.3453
Non-Hispanic White 81 (90) 27 (90) 25 (83) 29 (97)
Black/African American 8 (9) 3 (10) 4 (13) 1 (3)
Asian/Pacific Islander 1 (1) 0 (0) 1 (3) 0 (0)
Smoking status, n (%)a 0.9565
Nonsmoker 51 (57) 17 (57) 18 (60) 16 (53)
Current smoker 5 (6) 1 (3) 2 (7) 2 (7)
Past smoker 34 (38) 12 (40) 10 (33) 12 (40)
Age (years), mean (SEM) 59.4 (0.6) 58.2 (1.2) 59.1 (1.0) 60.8 (1.0) 0.2482
Body–mass index (kg/m2), mean (SEM) 26.9 (0.4) 25.9 (0.7) 27.1 (0.7) 27.9 (0.7)b 0.1368
SBP (mm Hg), mean (SEM) 121.8 (1.3) 120.1 (2.3) 121.1 (2.5) 124.3 (2.2) 0.4150
DBP (mm Hg), mean (SEM) 74.7 (0.9) 73.2 (1.2) 73.1 (1.8) 77.7 (1.6)c 0.0680
Heart rate (bpm), mean (SEM) 65.1 (1.0) 63.1 (1.2) 64.8 (1.0) 67.4 (1.8) 0.1760
MAC-Q score, mean (SEM) 29.2 (0.3) 29.1 (0.6) 29.2 (0.6) 29.1 (0.5) 0.9697
MMSE score, mean (SEM) 28.5 (0.2) 28.5 (0.3) 28.6 (0.3) 28.3 (0.3) 0.4746
VPA I score, mean (SEM) 23.7 (0.7) 23.2 (1.4) 24.2 (1.3) 23.8 (0.9) 0.8886
VPA II score, mean (SEM) 7.0 (0.2) 7.0 (0.3) 6.6 (0.4) 7.2 (0.3) 0.5187
aParticipant smoking status was defined as nonsmokers, current smokers (current use or use £6 months before screening), and past
smokers (use >6 months before screening).
bAlthough the overall comparison of all three groups was not significant, body–mass index (placebo vs. 900mg/day spearmint extract)
did reach significance ( p = 0.0482).
cAlthough the overall comparison of all three groups was not significant for DBP, placebo versus 900mg spearmint did reach significance
( p = 0.048).
*p-Values for the overall comparison were generated from an analysis of variance model without adjustments for multiple comparisons
(n= 30/group and an overall N= 90).
bpm, beats per minute; DBP, diastolic blood pressure; MAC-Q, Memory Assessment Clinic Scale Questionnaire; MMSE, Mini-Mental
State Exam; SBP, systolic blood pressure; SEM, standard error of the mean; VPA, Verbal Paired Associates.
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Sleep
Subjects were administered the LSEQ to evaluate getting
to sleep, quality of sleep, ease of awakening from sleep, and
alertness and behavior following wakefulness (Table 5). An
overall treatment effect [F(2,82) = 4.29, p = 0.0170] was
evident in ratings of getting to sleep. Further, between-group
comparisons showed that subjects consuming 900mg/day
spearmint extract reported improved ability to get to sleep
versus subjects consuming placebo [t(82)= 2.91, p = 0.0046,
d = 0.805]. An overall treatment effect was also observed
for behavior following wakefulness [F(2,82)=3.31, p=0.0415].
The pairwise comparison suggests that subjects consuming
spearmint extract at 900mg/day had improved behavior fol-
lowing wakefulness relative to subjects consuming 600mg/day
of spearmint extract [t(82) = -2.52, p = 0.0137]. No signifi-
cant differences were observed in quality of sleep or ease of
awakening from sleep.
Discussion
This study shows that supplementation with this dried
aqueous spearmint extract at 900mg/day for 90 days signifi-
cantly improved quality of working memory and spatial
working memory versus placebo in healthy subjects with
AAMI. Further, subjects taking the 900mg daily dose also
reported improvements in the ability to fall asleep and dem-
onstrated trends for improved ratings from subjective mood
assessments, including vigor-activity and TMD. These data
corroborate initial findings from a single-arm trial in which
supplementation with 900mg/day of this extract for 30 days
showed improvements in components of working memory.32
Working memory pertains to the ability to use and ma-
nipulate information stored within short-term memory.
Current evidence indicates that working memory decreases
with age, beginning in early adulthood.35 Wesnes reported a
decrease in working memory of roughly 10% per decade
after the age of 40 in healthy individuals (n= 2282; 18–87
years of age).36 Given this decrease with age, the im-
provements observed in the current study are promising as
quality of working memory and spatial working memory
improved by*15% and 9% over placebo, respectively. The
quality of working memory score at day 0 was lower in the
900mg/day spearmint group relative to the other treatments;
however, evaluation of the change from baseline incorpo-
rates this value and suggests improvement over placebo.
These data suggest that this extract could improve working
memory equivalent to that which may have diminished
over a decade of life. The identified improvements in
working memory, a hippocampal-dependent task, are further
supported by the previously reported reduction in oxidation
status in the hippocampus of SAMP8 mice after spearmint
extract supplementation.22
To our knowledge, this is the first randomized, double-
blind, placebo-controlled study to evaluate the effects of a
dried aqueous spearmint extract with high levels of RA
(‡14.5%) on cognitive performance after chronic adminis-
tration in a parallel design. There are indications that
compounds present within plants of the Lamiaceae family
could be beneficial for cognition as suggested by previous
research. Extracts of rosemary (Rosmarinus officinalis L.),
sage (Salvia officinalis L.), and lemon balm (Melissa offi-
cinalis L.), all members of the Lamiaceae family, have been
shown to benefit secondary memory, quality of memory,
and speed of memory, respectively, after acute dosing.10–12
However, there have been no published studies with similar
plant extracts (aqueous or otherwise), which have reported
working memory benefits after chronic supplementation.
These previous studies reported acute benefits utilizing a
crossover design after a single dose of the extracts.
Reduced sleep efficiency and quality have been correlated
with cognitive decline that occurs with age.37 Therefore, the
findings showing improvement in getting to sleep with
900mg/day spearmint supplementation are notable given
the age of the subjects (50–70 years) and the consistency of
these effects with improvements in working memory. The
reported differences in sleep ratings on the LSEQ after
90 days of supplementation for subjects taking 900mg/day
of extract were an average of 7.8mm greater than the pla-
cebo group. This improvement is consistent with effects
reported after administration of commonly used sleep aids
FIG. 4. Quality of working memory scores after 90 days of
spearmint supplementation. Supplementation with the spear-
mint extract at 900mg/day resulted in improved (overall
treatment effect, *p= 0.0435) quality of working memory
versus subjects consuming either placebo ( p= 0.0469) or
600mg/day ( p= 0.0212). Data are expressed as mean differ-
ence from baseline (day 0) for the daily averages– standard
error of the mean (n= 28–30/group).
FIG. 5. Spatial working memory distractor items correctly
identified after 90 days of spearmint supplementation.
Subjects supplemented for 90 days with spearmint extract at
900mg/day had improved (overall treatment effect,
*p = 0.0373) accuracy of spatial working memory versus
subjects consuming either placebo ( p= 0.0456) or 600mg/day
spearmint extract ( p = 0.0172). Data shown are the mean
difference from baseline (day 0) for the daily averages –
standard error of the mean (n = 28–30/group).
44 HERRLINGER ET AL.
typically administered before bed.38 While other studies have
reported improved quality of sleep after supplementation with
extracts from plants within the Lamiaceae family, these
studies typically use a blend of extracts administered be-
fore bedtime.39,40 Corroboration of these novel findings for
spearmint extract using more objective sleep measurement
tools is warranted.
Mood may play a role in cognitive decline with aging41;
therefore, the potential mood benefits were not surprising
given the observed improvements in both working memory
and sleep. There are limited data reporting the effects of
plant extracts within the Lamiaceae family on mood after
oral supplementation. Studies evaluating the effects of
lemon balm (M. officinalis L.) extract on mood identified
differences in calmness but inconsistent findings in alert-
ness.11,42 In addition, administration of sage (Salvia la-
vandulaefolia and S. officinalis) in both oil and dried forms
resulted in improved measures of calmness, alertness, and
contentedness.43,44 A notable difference in the published
studies on lemon balm and sage is the inclusion of young
Table 4. Subjective Ratings of Mood, from the Profile of Mood States Questionnaire,
Before and After 90 Days of Supplementation with Spearmint Extract
Mood factors
Placebo 600mg Spearmint extract 900mg Spearmint extract
Day 0 Day 90 Day 0 Day 90 Day 0 Day 90
Mean rating (SEM) p* Directiona
Tension-Anxiety 3.53 (0.53) 3.48 (0.51) 4.13 (0.59) 4.39 (0.95) 6.10 (0.89) 5.04 (0.62) 0.3411 Y
Depression-
Dejection
1.80 (0.42) 2.10 (0.59) 1.30 (0.48) 2.11 (0.66) 3.83 (1.14) 2.32 (0.79) 0.0862 Y
Anger-Hostility 0.73 (0.35) 0.86 (0.28) 0.53 (0.27) 1.25 (0.54) 2.07 (0.58) 1.54 (0.48) 0.1935 Y
Vigor-Activity 17.47 (1.26) 18.07 (1.30) 16.80 (1.42) 16.11 (1.66) 15.90 (1.27) 19.82 (1.17)b 0.0399 [
Fatigue-Inertia 3.40 (0.84) 3.79 (0.93) 2.50 (0.51) 3.75 (0.79) 4.30 (0.68) 3.86 (0.79) 0.2111 Y
Confusion-
Bewilderment
5.63 (0.67) 5.10 (0.73) 4.40 (0.43) 4.32 (0.53) 5.37 (0.63) 5.00 (0.67) 0.8448 Y
Total Mood
Disturbance
2.87 (1.93) 3.38 (2.58) 1.87 (1.50) 6.07 (2.85) 10.60 (3.49) 5.04 (2.28)c 0.0374 Y
Bold values indicate overall treatment effects, p< 0.05.
The Profile of Mood States (POMS Standard Form) questionnaire (65-item) was administered at baseline (day 0) and after 90 days of
spearmint extract or placebo supplementation. Subjects were asked to rate how they had been feeling in the past week as follows: not at all
(0), a little (1), moderately (2), quite a bit (3), extremely (4).
aThe arrow notes the direction of change that suggests improvement in the associated outcome.
b900mg/day spearmint extract versus placebo, p = 0.0646; 900mg/day spearmint extract versus 600mg/day spearmint extract, p = 0.0149.
c900mg/day spearmint extract versus placebo, p = 0.0832; 900mg/day spearmint extract versus 600mg/day spearmint extract, p = 0.0123.
*p-Values for the overall and pairwise comparisons in the intent-to treat sample were generated from a mixed-model repeated-measures
analysis of variance model based on the difference from baseline in mood ratings (n = 28–30/group).
SEM, standard error of the mean.
Table 5. Subjective Ratings of Sleep, from Leeds Sleep Evaluation Questionnaire,
Before and After 90 Days of Supplementation with Spearmint Extract
Placebo 600mg Spearmint extract 900mg Spearmint extract
Parameter Day 0 Day 90 Day 0 Day 90 Day 0 Day 90
Sleep factors (mm) Mean rating (SEM) p* Directiona
Ease of getting
to sleep
49.83 (0.95) 45.48 (2.15) 51.30 (0.87) 50.36 (1.70) 47.63 (0.91) 51.11 (1.36)b 0.0170 [
Quality of sleep 50.27 (0.37) 48.62 (3.20) 50.97 (1.12) 52.04 (2.23) 49.83 (0.57) 53.25 (1.98) 0.4267 [
Ease of awakening
from sleep
49.40 (0.40) 52.69 2.84) 48.63 (1.29) 50.54 (2.75) 52.10 (1.31) 54.14 (1.76) 0.9016 [
Alertness and
behavior after
wakefulness
52.20 (2.13) 59.31 (2.89) 55.03 (2.64) 53.50 (3.44)c 52.07 (1.83) 63.46 (2.78) 0.0415 [
Bold values indicate overall treatment effects, p< 0.05.
The Leed’s Sleep Evaluation Questionnaire was administered at baseline (day 0) and after 90 days of spearmint extract or placebo
supplementation. Subjects were asked to rate aspects of sleep by using 100mm visual analog scales flanked with antonyms (i.e., a rating of
50mm is neutral).
aThe arrow notes the direction of change that suggests improvement in the associated outcome.
b900mg/day spearmint extract versus placebo, p = 0.0046; 900mg/day spearmint extract versus 600mg/day spearmint extract, p = 0.0879.
c600mg/day versus placebo, p = 0.0892; 600mg/day versus 900mg/day spearmint extract, p = 0.0137.
*p-Values for the overall and pairwise comparisons in the intent-to-treat sample were generated from a mixed-model repeated-measures
analysis of variance model based on the difference from baseline in ratings of sleep (n= 28–30/group).
SEM, standard error of the mean.
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adults (18–30 years of age), crossover design, and acute
administration. In contrast, the current study included older
adults in a parallel design after chronic administration and
identified improvements in vigor-activity and TMD.
The major strength of this study is the randomized, double-
blind, placebo-controlled, parallel-group study design. Com-
pliance with study product consumption was greater than
98% in all groups. The CDR testing battery utilized is vali-
dated for populations with AAMI and shown to be sensitive
enough to detect the effects of acute and chronic nutritional
interventions. The computerized tests were carried out in a
parallel format to reduce practice effects, and training ses-
sions allowed subjects to acclimate to the testing battery.
Finally, subjects completed these tools in a supervised envi-
ronment where lighting and noise were controlled.
The limitations of this study include potential confounding
factors such as diet and lifestyle; however, to minimize these
factors, subjects were asked to maintain their habitual diet,
exercise routines, and sleep duration throughout the study.
Cognitive outcomes measured at multiple time points on each
test day were analyzed by using average daily values. One
criticism of this approach is that utilization of daily averages
may allow any acute effects from the predose assessment to
confound the chronic analysis. However, since acute differ-
ences were not evident for the individual tasks or composite
cognitive performance factors at any visit, to improve the
reliability of the measurements, outcome scores were aver-
aged across the -0.75, 0.5, 2, 4, and 6 h timepoints. There-
fore, the differences measured and reported within this study
best reflect what an individual might expect after a chronic
dosing regimen. In addition, it is important to note that since
this intervention included healthy older individuals, caution
should be taken when extrapolating the observed benefits to
those with more advanced stages of cognitive dysfunction.
In summary, healthy older subjects with AAMI taking
900mg/day of the spearmint extract improved their work-
ing memory and self-reported ability to get to sleep. Taken
together, these findings suggest that this dried aqueous spear-
mint extract, containing more than 50 phenolic compounds
including higher RA relative to native spearmint species,
shows promise as an ingredient for improved cognitive per-
formance, sleep and possibly mood, all of which may im-
prove quality of life.
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